Biomea Fusion to Participate in Upcoming Investor Conferences
Biomea Fusion will meet investors and present at two New York conferences in September 2026, with a webcast available for one presentation.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Biomea Fusion (BMEA) will participate in two investor conferences in September 2026 in New York. Management will attend Citi's 2026 Biopharma Back to School Conference for one-on-one investor meetings on September 10, 2026. The company will also present at the H.C. Wainwright 28th Annual Global Investment Conference at 11:00 a.m. ET on September 15, 2026, and hold additional one-on-one meetings. An audio webcast and replay of the H.C. Wainwright presentation will be available on Biomea’s website under Investors & Media.
Details
News Market Reaction – BMEA
On Sep 3, the day this news came out, BMEA closed 1.29% below the previous close. Our momentum scanner recorded 5 alerts for this stock that day. Relative volume reached 3.0x the daily average during tracking.
Data tracked by StockTitan Argus for the Sep 3 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN CARLOS, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Company” or “Company management”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that members of its management team will participate in the following upcoming investor conferences:
- Citi's 2026 Biopharma Back to School Conference: Biomea will participate in one-on-one investor meetings on September 10, 2026, in New York, NY.
- H.C. Wainwright 28th Annual Global Investment Conference: Biomea will present at 11:00 a.m. ET on September 15, 2026, in New York, NY. Management will also participate in one-on-one investor meetings during the conference.
An audio webcast of the presentation will be available on the News & Events page under the Investors & Media section of Biomea’s website. A replay of the webcast will be available following the presentation.
About Biomea Fusion
Biomea Fusion is a clinical-stage biopharmaceutical company advancing oral small molecule therapies, icovamenib and BMF-650, for diabetes and obesity. These programs target metabolic disorders, a global health challenge affecting nearly half of Americans and one-fifth of the world’s population. Biomea’s mission is to deliver transformative treatments that restore health for patients living with diabetes, obesity, and related conditions. We aim to cure.
Visit us at biomeafusion.com and follow us on LinkedIn, X and Facebook.
Contact:
Meichiel Jennifer Weiss
Sr. Director of Investor Relations and Corporate Development
ir@biomeafusion.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.